ADC-018

ADC-018 is a preclinical antibody-drug conjugate (ADC) being developed by iProgen Biotech in collaboration with Celltrion for the treatment of various oncology indications. The therapeutic candidate consists of a monoclonal antibody conjugated to a small-molecule cytotoxic payload using iProgen's proprietary site-specific conjugation technology. This technology is designed to enhance the stability and homogeneity of the conjugate, potentially improving its therapeutic index compared to traditional conjugation methods. As of 2024, the program is in the discovery phase, and the specific tumor-associated antigen targeted by the antibody component has not been publicly disclosed.